Two Sigma Investments LP Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Two Sigma Investments LP reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 62.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,054 shares of the biotechnology company's stock after selling 127,216 shares during the period. Two Sigma Investments LP owned 0.08% of Sarepta Therapeutics worth $9,126,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of SRPT. Capital International Investors grew its stake in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $126,315,000. Farallon Capital Management LLC lifted its holdings in Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock worth $348,368,000 after purchasing an additional 285,100 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its stake in Sarepta Therapeutics by 174.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 379,150 shares of the biotechnology company's stock valued at $46,101,000 after purchasing an additional 241,032 shares during the period. Finally, Alkeon Capital Management LLC grew its holdings in Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock valued at $103,819,000 after buying an additional 220,000 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on SRPT. Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "neutral" rating and issued a $40.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 22nd. Royal Bank of Canada reduced their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research note on Wednesday, May 7th. Finally, Morgan Stanley dropped their target price on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $122.61.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded up $1.41 during mid-day trading on Thursday, hitting $38.64. 1,654,150 shares of the stock traded hands, compared to its average volume of 1,798,326. Sarepta Therapeutics, Inc. has a 12-month low of $34.10 and a 12-month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.80 billion, a PE ratio of 30.92 and a beta of 0.85. The business's 50-day moving average price is $52.32 and its 200 day moving average price is $92.86.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.